Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma
Research output: Contribution to journal › Journal article › peer-review
Standard
Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. / Wewer Albrechtsen, Nicolai J; Hornburg, Daniel; Albrechtsen, Reidar; Svendsen, Berit; Toräng, Signe; Jepsen, Sara L; Kuhre, Rune E; Hansen, Marie; Janus, Charlotte; Floyd, Andrea; Lund, Asger; Lauritsen, Tina Vilsbøll; Knop, Filip K; Vestergaard, Henrik; Deacon, Carolyn F; Meissner, Felix; Mann, Matthias; Holst, Jens J; Hartmann, Bolette.
In: EBioMedicine, Vol. 7, 05.2016, p. 112-120.Research output: Contribution to journal › Journal article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma
AU - Wewer Albrechtsen, Nicolai J
AU - Hornburg, Daniel
AU - Albrechtsen, Reidar
AU - Svendsen, Berit
AU - Toräng, Signe
AU - Jepsen, Sara L
AU - Kuhre, Rune E
AU - Hansen, Marie
AU - Janus, Charlotte
AU - Floyd, Andrea
AU - Lund, Asger
AU - Lauritsen, Tina Vilsbøll
AU - Knop, Filip K
AU - Vestergaard, Henrik
AU - Deacon, Carolyn F
AU - Meissner, Felix
AU - Mann, Matthias
AU - Holst, Jens J
AU - Hartmann, Bolette
N1 - Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2016/5
Y1 - 2016/5
N2 - Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this platform by studying a hitherto neglected glucose- and appetite-regulating gut hormone, namely, oxyntomodulin. Our results show that the secretion of oxyntomodulin in patients with type 2 diabetes is significantly impaired, and that its level is increased by more than 10-fold after gastric bypass surgery. Furthermore, we report that oxyntomodulin is co-distributed and co-secreted with the insulin-stimulating and appetite-regulating gut hormone glucagon-like peptide-1 (GLP-1), is inactivated by the same protease (dipeptidyl peptidase-4) as GLP-1 and acts through its receptor. Thus, oxyntomodulin may participate with GLP-1 in the regulation of glucose metabolism and appetite in humans. In conclusion, this mass spectrometry-based platform is a powerful resource for identifying and characterizing metabolically active low-abundance peptides.
AB - Low-abundance regulatory peptides, including metabolically important gut hormones, have shown promising therapeutic potential. Here, we present a streamlined mass spectrometry-based platform for identifying and characterizing low-abundance regulatory peptides in humans. We demonstrate the clinical applicability of this platform by studying a hitherto neglected glucose- and appetite-regulating gut hormone, namely, oxyntomodulin. Our results show that the secretion of oxyntomodulin in patients with type 2 diabetes is significantly impaired, and that its level is increased by more than 10-fold after gastric bypass surgery. Furthermore, we report that oxyntomodulin is co-distributed and co-secreted with the insulin-stimulating and appetite-regulating gut hormone glucagon-like peptide-1 (GLP-1), is inactivated by the same protease (dipeptidyl peptidase-4) as GLP-1 and acts through its receptor. Thus, oxyntomodulin may participate with GLP-1 in the regulation of glucose metabolism and appetite in humans. In conclusion, this mass spectrometry-based platform is a powerful resource for identifying and characterizing metabolically active low-abundance peptides.
U2 - 10.1016/j.ebiom.2016.03.034
DO - 10.1016/j.ebiom.2016.03.034
M3 - Journal article
C2 - 27322465
VL - 7
SP - 112
EP - 120
JO - EBioMedicine
JF - EBioMedicine
SN - 2352-3964
ER -
ID: 162643439